Please assess the completion status of the following clinical trial:

Trial Title: Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female participants 18 years old or older.~* Participant must be able to understand the study procedures and agree to participate in the study by providing written informed consent.~* Participant must have received niraparib within the Spanish expanded access program (EAP).~* Patients must have received at least 1 week of treatment with niraparib.~* Histological diagnosis of high grade serous ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.~* Participants must have completed at least 2 previous courses of platinum-containing therapy (e.g., carboplatin, oxaliplatin, or cisplatin).~* For the penultimate (next to last) platinum-based chemotherapy course prior to enrolment on the program the patient must have platinum sensitive disease after this treatment; defined as achieving a response (complete response (CR) or partial response (PR)) and disease progression occurring no sooner than 6 months, after completion of the last dose of platinum chemotherapy.~* For the last chemotherapy course prior to inclusion in the program the patient must have received a platinum-containing regimen for a minimum of 4 cycles.~* For the last chemotherapy course prior to inclusion in the program the Patient must have achieved a partial (PR) or complete (CR) tumor response.~* The last platinum regimen does not necessarily have to immediately follow the next to last (penultimate) platinum regimen. For example, if a patient received a non-platinum regimen between the penultimate platinum regimen and last platinum regimen, they could be eligible, so long as they meet all entry criteria.~* When entering the EAP, patients must have met the following:~  * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.~ * Adequate organ function - Absolute neutrophil count (ANC) ≥ (greater than or equal to) 1,500/μL.~ * Adequate organ function - Platelets ≥ (greater than or equal to) 100,000/μL.~ * Adequate organ function - Hemoglobin ≥ (greater than or equal to) 9 g/dL.~ * No transfusions of erythrocytes or platelets within 2 weeks prior to assessing adequate hematological blood counts as listed above.~Exclusion Criteria:~* Patients without medical record available (lost, empty or unretrievable clinical information).~* Patients who decline consent.~* Patients who are deceased with prior express order to preserve their data.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).